Inventor · disambiguated record
Siegfried Ansorge
Also filed as: ANSORGE SIEGFRIED
10 granted patents·8 pending applications·42 citations·filing 2001–2011
84Inventor score
Technology areasA61P
Files withANSORGE SIEGFRIED8IMTM GMBH6ESPARMA GMBH1INST MEDIZINTECHNOLOGIE MAGDEB1KEYNEUROTEK PHARMACEUTICALS AG1
Top patents by PatentIndex Score
18 records- 0173US8263636B2Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseasesANSORGE SIEGFRIED·Filed 2004·Granted Sep 11, 2012·17 cites·14 claims
- 0273US7858655B2Drug preparation comprising α-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseasesKEYNEUROTEK PHARMACEUTICALS AG·Filed 2004·Granted Dec 28, 2010·15 cites·14 claims
- 0370US7229969B2Combinations of enzyme inhibitors and the use thereofIMTM GMBH·Filed 2001·Granted Jun 12, 2007·9 cites·12 claims
- 0456US7429614B2Medicament containing an effector of the glutathione metabolism together with α-lipoic acid for treating diabetes mellitusESPARMA GMBH·Filed 2002·Granted Sep 30, 2008·1 cites·7 claims
- 0547US7803776B2Combined use of enzyme inhibitors and of pharmaceutical compositions thereofINST MEDIZINTECHNOLOGIE MAGDEB·Filed 2007·Granted Sep 28, 2010·0 cites·19 claims
- 0642US2007212339A1Use Of At Least One Effector Of Glutathione Metabolism Together With Alpha-Lipoic Acid For The Treatment Of Chronically Obstructive Lung DiseasesIMTM GMBH·Filed 2004·Application pending·0 cites
- 0740US7425532B2Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitorsIMTM GMBH·Filed 2003·Granted Sep 16, 2008·0 cites·9 claims
- 0839US2011117069A1Method for activating regulatory t-cellsIMTM GMBH·Filed 2008·Application pending·0 cites
- 0938US2007037785A1Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseasesANSORGE SIEGFRIED·Filed 2004·Application pending·0 cites
- 1038US2007037752A1Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseasesANSORGE SIEGFRIED·Filed 2004·Application pending·0 cites
- 1137US2007042938A1Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblastsANSORGE SIEGFRIED·Filed 2004·Application pending·0 cites
- 1234US2004147434A1Use of enzyme inhibitors of the dipeptidypeptidase iv (ec3.3.14.5) in addition to the aminopeptidase n (ec 3.4.11.2), individually or in a combination thereof, and pharmaceutical preparations thereof for the prevention and/or therapy of ischaemia-caused acute and chronic neurodegenerative process and illnesses, for exampleANSORGE SIEGFRIED·Filed 2001·Application pending·0 cites
- 1333US7683034B2Use of enzyme inhibitors of aminopeptidase N and/or dipeptidylpeptidase IVIMTM GMBH·Filed 2003·Granted Mar 23, 2010·0 cites·4 claims
- 1433US7531567B2Use of a medicament containing an effector of the glutathione metabolism together with α-lipoic acid in kidney replacement therapySERUMWERK BERNBURG AG·Filed 2002·Granted May 12, 2009·0 cites·21 claims
- 1530US8470855B2Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseasesANSORGE SIEGFRIED·Filed 2006·Granted Jun 25, 2013·0 cites·29 claims
- 1630US7485626B2Combinations of enzyme inhibitor-containing preparations and the use thereofIMTM GMBH·Filed 2001·Granted Feb 3, 2009·0 cites·7 claims
- 1728US2012028995A1Novel compounds for medical use as peptidase effectorsANSORGE SIEGFRIED·Filed 2011·Application pending·0 cites
- 1827US2012258960A1Novel multifunctional peptidase inhibitors, especially for medical useANSORGE SIEGFRIED·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Siegfried Ansorge files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →